Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
391 GLP-1 and GLP-1 analogs exert their effects on food intake and body weight through a myriad of neural substrates, encompassing several hypothalamic nuclei (including the arcuate nucleus of the hypothalamus, periventricular hypothalamus, and lateral hypothalamic area), hindbrain nuclei (such as the parabrachial nucleus and medial nucleus tractus solitarius), the ventral subregion of the hippocampus (vHP), and nuclei embedded within the mesolimbic reward circuitry (including the ventral tegmental area, VTA, and nucleus accumbens, NAc)
Persistent nausea or vomiting that is not improving after the first few weeks, or that is significantly affecting their ability to eat or function Mood changes that are lasting beyond the initial adjustment period, or that are notably affecting their daily life or your relationship Significant fatigue that is not improving as treatment progresses Signs of nutritional difficulty, such as extreme weakness, hair loss, or other symptoms that suggest they are not meeting nutritional needs Any change in how the medication is making them feel that they seem reluctant to raise because they do not want to seem like they are complaining or asking for the treatment to stop Your role here is not to diagnose or to manage their treatment
Some patients may also benefit from pharmacy discount programs or generic alternatives when they become available
